EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Innovative, complementary and alternative therapy in inflammatory bowel diseases: A broad 2020s update

Letizia Masi, Cristina Ciuffini, Valentina Petito, Laura Francesca Pisani, Loris Riccardo Lopetuso, Cristina Graziani, Daniela Pugliese, Lucrezia Laterza, Pierluigi Puca, Federica Di Vincenzo, Marco Pizzoferrato, Daniele Napolitano, Laura Turchini, Valeria Amatucci, Elisa Schiavoni, Giuseppe Privitera, Laura Maria Minordi, Maria Chiara Mentella, Alfredo Papa, Alessandro Armuzzi, Antonio Gasbarrini, Franco Scaldaferri

Frontiers in Gastroenterology · 2022

DOI: 10.3389/fgstr.2022.1022530 ↗
AbstractBibliografische Angaben

Abstract

Inflammatory bowel diseases (IBD) are chronic disabling conditions with a complex and multifactorial etiology, which is still not completely understood. In the last 20 years, anti-TNF-α antagonists have revolutionized the treatment of IBD, but many patients still do not respond or experience adverse events. Therefore, new biological therapies and small molecules, targeting several different pathways of gut inflammation, have been developed of which some have already been introduced in clinical practice while many others are currently investigated. Moreover, therapeutic procedures such as leukocytapheresis, fecal microbiota transplant and stem cell transplantation are currently being investigated for treating IBD. Lastly, complementary and alternative medicine has become a field of interest for gastroenterologist to reduce symptom burden in IBD patients. In this comprehensive and updated review, a novel classification of current and developing drugs is provided.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →